Nuveen Asset Management LLC Increases Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Nuveen Asset Management LLC grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 108.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 667,634 shares of the company's stock after buying an additional 347,993 shares during the quarter. Nuveen Asset Management LLC owned about 0.98% of Replimune Group worth $8,085,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Replimune Group by 8.3% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 241,570 shares of the company's stock valued at $2,925,000 after buying an additional 18,448 shares during the period. Millennium Management LLC lifted its holdings in shares of Replimune Group by 3.0% in the 4th quarter. Millennium Management LLC now owns 1,189,662 shares of the company's stock valued at $14,407,000 after buying an additional 34,841 shares during the period. J. Goldman & Co LP lifted its holdings in shares of Replimune Group by 639.5% in the 4th quarter. J. Goldman & Co LP now owns 112,683 shares of the company's stock valued at $1,365,000 after buying an additional 97,446 shares during the period. Graham Capital Management L.P. lifted its holdings in shares of Replimune Group by 6.1% in the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock valued at $365,000 after buying an additional 1,731 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of Replimune Group by 12.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 972,575 shares of the company's stock valued at $11,778,000 after buying an additional 104,892 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Piper Sandler lifted their price objective on Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a report on Monday. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, HC Wainwright lifted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $19.75.

Replimune Group Price Performance

Shares of NASDAQ REPL traded up $0.59 during trading on Monday, reaching $9.57. The company had a trading volume of 2,316,580 shares, compared to its average volume of 944,325. Replimune Group, Inc. has a twelve month low of $4.93 and a twelve month high of $17.00. The stock has a market capitalization of $737.72 million, a PE ratio of -3.12 and a beta of 0.68. The stock has a 50-day moving average price of $8.37 and a two-hundred day moving average price of $11.07. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the business earned ($0.25) earnings per share. As a group, sell-side analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Transactions at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the sale, the director now owns 1,405,071 shares of the company's stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider now directly owns 146,933 shares of the company's stock, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock valued at $603,655 over the last three months. 8.80% of the stock is currently owned by insiders.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.